Business
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results e
About this update from Tectonic Therapeutic, Inc.
[{"type":"image","alt":"Tectonic Therapeutic","displaySize":"","headline":null,"caption":"Tectonic Therapeutic","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/09e29d13a5147d733b1f52191d8f4124"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/23AfX4_2qGPR9uUgIzr4Uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/09e29d13a5147d733b1f52191d8f4124","width":300,"height":81}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)","length":261,"tagName":"p"}]},{"val":[{"type":"text","content":"Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, Serbia","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Part B of the TX45 Phase 1b trial initiated in March with topline results expected in the second half of 2025","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing TX45 APEX Phase 2 trial continues to enroll with topline results expected in 2026","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents were $306.2 million as of March 31, 2025, including the private placement net proceeds raised in February 2025, expected to provide cash runway into Q4 2028","length":182,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":805,"olType":false},{"type":"text","content":"WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent business highlights.","length":431,"tagName":"p"},{"type":"text","content":"“During the first quarter, we continued to make meaningful progress across our proprietary pipeline and fortified our cash positio...